Wounded Warrior Project adds J&J vet, West Point grad to board
PHILADELPHIA — Wounded Warrior Project on Tuesday boosted its board of directors with both military and business experience with the appointment of Kathleen Widmer, a president at Johnson & Johnson and West Point graduate.
Widmer becomes WWP's tenth board member. Her background includes nearly 25 years with Johnson & Johnson, most recently as president of Johnson & Johnson Consumer, OTC Division since 2015. Widmer graduated from West Point in 1983 and served five years in the U.S. Army. Widmer holds a Masters of Business Administration in Marketing and Marketing Management from Oklahoma City University.
"We're excited Kathleen Widmer is able to bring her passion for the military to our board of directors," stated WWP CEO Lt. Gen. (Ret.) Mike Linnington. "Dating back to the Spanish-American War, Johnson & Johnson has shown a commitment to the veteran community. Kathleen's growth through that organization will help us as we continue evolving to best serve this generation of wounded warriors."
During Widmer's time with Johnson & Johnson, she has served as VP marketing, director marketing, marketing manager and manufacturing business unit manager. Widmer also served as chief marketing officer of Elizabeth Arden from 2010-2014.
She currently serves on the board of directors for Texas Roadhouse, the Consumer Healthcare Products Association and Community Anti-Drug Coalitions of America.
Clinical study supports use of OmniLean Salacia Extract for appetite reduction
MORRISTOWN, N.J. — In the recent CARBS (an acronym for Carbohydrate, Appetite Reduction, Blood Sugar and Satiety) study, researchers at Rutgers University observed that a proprietary salacia extract demonstrated appetite reduction, satiety and blood sugar management benefits.
Native to the Indian subcontinent, salacia is a genus of woody climbers well known for its traditional use in Ayurveda as a medicinal food supplement for various health conditions.
CARBS was a randomized, double blind, placebo-controlled, 3-way cross-over study and the first to examine the effects of a proprietary extract of Salacia chinensis (from OmniLean) on glycemic indices and gut hormones after a meal. OmniLean, taken with a meal, resulted in an improved glycemic response and changes in gut hormones in healthy overweight/obese individuals, thereby reducing blood sugar spikes and impacting appetite and satiety.
"The herb, Salacia chinensis, was shown to reduce glycemic indices and affect gut peptides after a meal. What does this mean? It means Salacia chinensis from OmniLean may be an appetite modulator, and because it lowers glycemic indices, would be beneficial to persons at risk for diabetes including overweight/obese person," stated Sue Shapses, one of the lead researchers on the CARBS Study.
"The myriad complexities of being overweight need to be addressed by a multipronged approach including diet and exercise, but may also benefit greatly by making a small change such as incorporating a natural supplement like OmniLean to your daily regimen," said Abhijit Bhattacharya, president of OmniActive Health Technologies, producers of OmniLean Salacia Extract. "The CARBS Study demonstrated that OmniLean reduced the feeling of hunger and reduced spikes in blood sugar—key components of weight management—which may be the missing piece for a vast population struggling with maintaining a healthy weight."
FDA approves new Rx treatment for urinary tract infections
SILVER SPRING, Md. — The U.S. Food and Drug Administration earlier this week approved Rempex Pharmaceuticals' Vabomere for adults with complicated urinary tract infections, including a type of kidney infection, pyelonephritis, caused by specific bacteria.
Vabomere is a drug containing meropenem, an antibacterial, and vaborbactam, which inhibits certain types of resistance mechanisms used by bacteria.
“The FDA is committed to making new safe and effective antibacterial drugs available,” stated Edward Cox, director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research. “This approval provides an additional treatment option for patients with cUTI, a type of serious bacterial infection.”